Results 21 to 30 of about 1,457,629 (200)

Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases

open access: yesFrontiers in Oncology, 2021
Vitreoretinal lymphoma (VRL) is a rare intraocular malignancy, and standard treatment approaches have not been defined yet. Bruton tyrosine kinase inhibitors are found to be effective in the treatment of primary central nervous system diffuse large B ...
Liang Wang, Wenxue Guan, Xiaoyan Peng
doaj   +1 more source

Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to VEGF-R tyrosine kinase inhibition [PDF]

open access: yes, 2009
This paper was presented at the 2nd Micro and Nano Flows Conference (MNF2009), which was held at Brunel University, West London, UK. The conference was organised by Brunel University and supported by the Institution of Mechanical Engineers, IPEM, the ...
Bjorndahl, MA   +7 more
core   +6 more sources

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

open access: yesClinical Hematology International, 2022
The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease.
Obada Ababneh   +4 more
doaj   +1 more source

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. [PDF]

open access: yes, 2017
Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.
Gavrilovic, Igor T.   +101 more
core   +2 more sources

Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome

open access: yesFrontiers in Immunology, 2022
Schnitzler syndrome is a rare adult-onset acquired autoinflammatory disorder typically characterized by chronic urticarial rash and immunoglobulin M (IgM) (rarely IgG) monoclonal gammopathy.
Yuehua Huang   +6 more
doaj   +1 more source

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A

open access: yesHaematologica, 2019
Hemophilia A is a rare hemorrhagic disorder caused by the lack of functional pro-coagulant factor VIII. Factor VIII replacement therapy in patients with severe hemophilia A results in the development of inhibitory anti-factor VIII IgG in up to 30% of ...
Sandrine Delignat   +7 more
doaj   +1 more source

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus

open access: yesFrontiers in Medicine, 2021
Bruton Tyrosine Kinase (BTK) has a key role in multiple pathways involved in inflammation and autoimmunity. Therefore, BTK has become a new therapeutic target for a group of hematologic and autoimmune disorders.
Aikaterini Patsatsi, Dedee F. Murrell
doaj   +1 more source

BTK (Bruton agammaglobulinemia tyrosine kinase) [PDF]

open access: yes, 2009
Review on BTK (Bruton agammaglobulinemia tyrosine kinase), with data on DNA, on the protein encoded, and where the gene is ...
van, Loo PF, Hendriks, RW
core   +1 more source

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

open access: yesMetabolism Open, 2021
Coronavirus disease 2019 (COVID-19) is first detected in December 2019 in Wuhan, China which is a new pandemic caused by SARS-COV-2 that has greatly affected the whole world.
Zemene Demelash Kifle
doaj   +1 more source

Home - About - Disclaimer - Privacy